Hyperpolarized 13-C-pyruvate

Phase 2Small molecule

MM.D. Anderson Cancer Center

Hyperpolarized 13-C-pyruvate is one of 217 small molecule programs targeting Glioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

216

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaActive, not recruiting

Pancreatic CystsActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

MeningiomaActive, not recruiting

Prostate CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Thyroid CancerActive, not recruiting

GliomaPhase 1

Active, not recruiting

Pancreatic CystsPhase 1

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Active, not recruiting

MeningiomaPhase 1

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Ovarian CancerPhase 1

Active, not recruiting

Thyroid CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Hyperpolarized 13-C-pyruvate

MM.D. Anderson Cancer Center

Phase 2

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Trexall

Alnylam Pharmaceuticals

Preclinical

—5

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 9

Prednisone/prednisolone

Roche

Preclinical

3 10

Triptorelin Pamoate

Ipsen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

MRI Scan

NCT04258462

Q1 2027

Phase 1Recruiting

Glioma

NCT04540107

Phase 1Recruiting

Pancreatic Cysts

NCT05873699

Q2 2027

Phase 1Recruiting

Thyroid Cancer

NCT04589624

Q3 2027

Phase 1Recruiting

Meningioma

NCT06014905

Clinical

Trials by Indication[1]

Glioma2 trials

Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT03830151·13 enrolled

Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma

Recruiting·SSusan Chang·Phase 1·NCT04540107·300 enrolled

Prostate Cancer2 trials

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT03581500

Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Recruiting·UUniversity of California, San Francisco·Phase 2·NCT03933670·60 enrolled

MRI Scan1 trial

Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors

Active, not recruiting·ZZhen Wang, MD·Phase 2·NCT04258462·54 enrolled

Thyroid Cancer1 trial

An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT04589624·42 enrolled

Central Nervous System Tumor1 trial

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors

Completed·—·Phase 1·NCT03565367·9 enrolled

4 more indications

Pancreatic Ductal Adenocarcinoma1 trial

Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma

Terminated·ZZhen Wang, MD·Phase 2·NCT04565327·7 enrolled

Ovarian Cancer1 trial

Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging

Suspended·MM.D. Anderson Cancer Center·Phase 1·NCT05866679·30 enrolled

Pancreatic cysts1 trial

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT05873699·20 enrolled

Meningioma1 trial

Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Recruiting·JJavier Villaneuva-Meyer, MD·Phase 1·NCT06014905·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Hyperpolarized 13-C-pyruvate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized 13-C-pyruvate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized 13-C-pyruvate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — M.D. Anderson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MM.D. Anderson Cancer Center

Hyperpolarized 13-C-pyruvate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Glioma2 trials

Prostate Cancer2 trials

MRI Scan1 trial

Thyroid Cancer1 trial

Central Nervous System Tumor1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Ovarian Cancer1 trial

Pancreatic cysts1 trial

Meningioma1 trial

References

Drug Info

Quick Facts

Related News